Genzyme Honors Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation Program Awards

  Genzyme Honors Innovation in Gaucher Disease Research through Its 2012
  Gaucher Generation Program Awards

Business Wire

CAMBRIDGE, Mass. -- November 26, 2012

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the
recipients of the 2012 Gaucher Generation Program awards, an annual program in
its fifth year that awards scientists and clinicians engaged in innovative
Gaucher disease research.

Genzyme’s Gaucher Generation program provides funding to researchers
throughout the world to stimulate and support the advancement of medical
knowledge in Gaucher disease. An independent committee of international
Gaucher disease experts reviewed the research proposals and selected the most
meritorious applications. This year, two “New Investigator Awards” were given,
with each recipient receiving $100,000 over two years, as well as one
“Established Investigator Award” with an award of $150,000 over two years.

“The Gaucher Generation Program represents Genzyme’s ongoing commitment to
enhance care and support of the global Gaucher community, with the ultimate
goal of transforming the lives of patients,” said Genzyme’s Senior Vice
President and Head of Rare Diseases, Rogerio Vivaldi, MD. “As world-renowned
thought leaders, each of these recipients will make a meaningful contribution
to further the understanding of Gaucher disease. Genzyme has been committed to
serving the Gaucher community for over 20 years, and we are proud to support
these award recipients in their important work.”

This year’s recipients are:

New Investigator Awards:

  *Gustavo Tiscornia, PhD, Assistant Professor in the Department of
    Biomedical Sciences and Medicine and Center for Molecular and Structural
    Biomedicine at the University of Algarve, Faro, Portugal. Dr. Tiscornia’s
    project is entitled “Development of an induced pluripotent stem cell model
    of neuronopathic Gaucher’s Disease for investigating mechanisms of
    pathogenesis and small molecule testing.” Dr. Tiscornia will focus on the
    use of stem cells to study Gaucher disease type 2, which involves the
    nervous system.
  *Elena Pavlova, MD, PhD, Addenbrooke’s Hospital, University of Cambridge,
    Cambridge, UK. In Dr. Pavlova’s project entitled, “Lymphoma in Gaucher
    disease – studies of causation and potential cure,” she will focus her
    efforts to better understand why patients with Gaucher disease have an
    increased risk of cancer.

Established Investigator Award:

  *Pramod K Mistry, MD, PhD, Professor of Pediatrics and Internal Medicine,
    Chief, Pediatric Hepatology, and Director, National Gaucher Disease
    Treatment Center at Yale University School of Medicine, New Haven, Conn.,
    USA. Dr. Mistry’s project is entitled “Studies to delineate specific
    phenotypes of Gaucher disease and decipher respective biomarker signatures
    and genetic underpinnings.” Dr. Mistry will seek to better understand how
    genes impact clinical and biochemical manifestations in patients with
    Gaucher disease.

For the 2012 application year, an international committee of Gaucher disease
experts scored the research proposals. Submissions were considered on the
basis of scientific merit, adequacy of the experimental design, and
feasibility of the proposed study. Higher consideration was given to proposals
that had the potential for improving patient outcomes. The judges were blinded
to the identity of the applicants until final decisions were made. More
information on Genzyme’s Gaucher Generation Program, including previous
recipients, can be found at:
http://www.gauchercare.com/healthcare/generation.aspx.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at
www.genzyme.com.

Genzyme^® is a registered trademark of Genzyme Corporation. All rights
reserved.

Contact:

Genzyme
Ingrid Esser, 617-768-6699
ingrid.esser@genzyme.com
 
Press spacebar to pause and continue. Press esc to stop.